ArticleJournal of neuroengineering and rehabilitation2026
Gamified electromyographic biofeedback for people with tetraplegia from SCI is enjoyable, results in high-dosage therapy, increases muscle electrical activity, and may improve arm function, a pilot study.
Article in Journal of neuroengineering and rehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndividuals with tetraplegia due to spinal cord injury (SCI) place a high priority on improving arm function for their independence and quality of life. Animal studies have shown a therapeutic benefit of much higher therapeutic dosages than obtained in clinical practice. Electromyographic (EMG) biofeedback is validated in people with SCI and can produce high dosage therapy. The goal of this pilot study is to test if gamified electromyographic (EMG) biofeedback can address this need by quantifying (1) participant enjoyment, (2) dosage of muscle activations, (3) increases in muscle activation, and (4) improvements in arm function measured with the Capabilities of Upper Extremity Test (CUE-T).
methodsAdults with traumatic complete and incomplete cervical SCI with volitional arm movement wore wearable sensors measuring EMG from paretic upper extremity muscles to control interactive games. Participants engaged in repetitive muscle actions for 10 min per muscle, targeting four muscles per 40-minute session. Participants with an acute SCI completed 1–2 sessions, while participants with a chronic SCI completed 8–12 sessions. All participants completed the Physical Activity Enjoyment Scale (PACES), and had MVC assessed at the beginning and end of each session, with EMG recorded during gameplay. Chronic participants performed the CUE-T at baseline and at the conclusion of their biofeedback sessions.
resultsThe study enrolled 28 acute participants and 6 chronic participants. Most participants performed more than 300 repetitions in a session, with some achieving over 1,500. The majority (31/34) of participants reported enjoying the games (PACES > 63). The average MVC improved by 23.8% per session (p < 0.001). 2 of 3 chronic participants who completed the baseline and conclusion CUE-T showed an increase over the minimal clinically important difference (> 7.7).
conclusionGamified EMG biofeedback with wearable sensors produces an enjoyable, high-repetition therapy of over 300 repetitions in most compared to the 20–50 repetitions seen in usual therapy. Participants showed improvements in muscle EMG activity. Chronic participants may even improve their arm function as measured by the CUE-T. No adverse effects were seen except self-resolving muscle soreness. This therapy has the potential to enable people with SCI to perform fun and effective home therapy, which will be further assessed in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.